Ipsen
Generated by Meeveem AI
"Transforming lives through targeted medicines in oncology, rare disease and neuroscience"
About Ipsen
Ipsen is a global biopharmaceutical company developing and commercialising medicines in oncology, rare disease and neuroscience. Its portfolio includes treatments for neuroendocrine tumours, rare bone disease and neurological conditions such as spasticity. The company combines internal research with partnerships involving biotechnology businesses and academic institutions.
Founded in 1929 and headquartered in Paris, Ipsen had 5,535 employees worldwide at the end of 2025, with teams in 42 countries and medicines reaching patients in more than 100 countries. Its UK operations span research and development, manufacturing and commercial activities, with a commercial and corporate hub in London and a neuroscience development and production site in Wrexham.
Learning and development
Ipsen runs annual development-plan campaigns for employees, followed by individual action plans. Its group development offer includes mentoring and a coaching platform rolled out globally. The company reported an average of 27 training hours per employee in 2025, alongside programmes supporting team effectiveness and leadership development.
5535
Team Members
1929
Founded
Pharma
Sector
Hybrid
Work Environment